U.S. Patent 8,632,802: Scope, Claim Construction, Patent Landscape, and Generic Entry Risk

U.S. Patent No. 8,632,802 protects drug-in-adhesive transdermal systems using specified acrylic polymer compositions, selected soft and hard monomers, controlled drug loading, and an express exclusion of acrylic polymers polymerized with methacrylic acid. The strongest coverage is directed to the polymer chemistry itself, rather than to a particular drug, dosage strength, patch geometry, or therapeutic indication. Claims 1, 19, and 20 are the independent claims. The patent creates meaningful formulation risk for patches using the claimed acrylic adhesive architecture, but substantial design-around routes exist through different monomer ratios, methacrylic-acid-containing acrylics, nonacrylic adhesives, or alternative delivery structures.

What does U.S. Patent 8,632,802 protect?

The patent covers a transdermal drug delivery system in which one or more drugs are incorporated into a polymer composition containing at least one acrylic-based polymer. The acrylic polymer must be formed from:

A soft acrylic monomer with a glass-transition temperature, or Tg, of approximately -70°C to -10°C.
A hard acrylic monomer with a Tg of approximately -5°C to 120°C.
A soft-monomer concentration of 50% to 70% by weight of the acrylic polymer.
A hard-monomer concentration of 30% to 50% by weight of the acrylic polymer.
No methacrylic acid monomer in any acrylic-based polymer present in the polymer composition.

The claims also cover drug loading from 0.1% to approximately 50% by weight, crystalline drugs, specified drug molecules, blends with rubber or silicone polymers, backing layers, and transdermal administration.

The principal inventive boundary is the combination of polymer composition, monomer identity or Tg, monomer ratio, drug incorporation, and the exclusion of methacrylic acid.

How many independent claims does U.S. Patent 8,632,802 have?

The issued claims contain three independent claim categories:

Claim	Category	Core subject matter
1	Product	Drug-containing transdermal system with defined soft/hard acrylic polymer composition
19	Method	Transdermal administration using the system of claim 1
20	Product	Drug-containing system using specified soft and hard monomer lists and broader ratio ranges

Claims 2-18 depend from claim 1. Claim 20 is an independent product claim with a different monomer-selection structure and broader composition ranges.

What are the key limitations of claim 1?

Claim 1 is the broadest and commercially most important composition claim. An accused patch would generally need to satisfy each material limitation.

Polymer composition

The claim requires at least one acrylic-based polymer. The polymer must be polymerized with both a soft acrylic monomer and a hard acrylic monomer.

The soft monomer must fall within the stated Tg range and constitute 50%-70% of the acrylic polymer. The hard monomer must fall within its own Tg range and constitute 30%-50%.

The two percentage ranges overlap at their boundaries and ordinarily imply a two-component balance totaling approximately 100%. The wording "include" is open-ended, so the claim may permit additional comonomers, crosslinkers, tackifiers, or other polymer constituents, provided the required soft and hard monomer limitations remain satisfied.

Global exclusion of methacrylic acid

The claim states that all acrylic-based polymers present in the polymer composition must be free of polymers polymerized with methacrylic acid monomers.

This is broader than a limitation on the principal acrylic polymer. If a patch contains two acrylic polymers and either one was polymerized with methacrylic acid, the global limitation may not be met. This limitation materially narrows the claim and provides a direct formulation design-around.

Drug incorporation

The drug must be incorporated into the polymer composition and must constitute 0.1%-50% by weight of the transdermal drug delivery system.

The claim does not require a particular drug. Claims 2 and 3 narrow the coverage to crystalline drugs and then to estradiol, norethindrone acetate, testosterone, or scopolamine.

Which drugs are specifically covered?

Claim 3 identifies four crystalline drugs:

Drug	Transdermal relevance
Estradiol	Hormone replacement products and estrogen patches
Norethindrone acetate	Combination hormone replacement systems
Testosterone	Hormonal replacement products
Scopolamine	Antiemetic and motion-sickness patches

The patent is not limited to these molecules. They are dependent-claim species that may receive narrower, potentially stronger protection if the broader claim is challenged.

Claims 4-6 create nested drug-loading ranges:

Claim	Drug concentration
1	0.1%-50%
4	Approximately 0.3%-30%
5	Approximately 0.5%-15%
6	Approximately 1%-10%

A product falling within a narrower range may infringe both the broader claim and the applicable dependent claim, assuming the remaining limitations are met.

What monomers are covered by claims 7-12?

Claims 7 and 8 narrow the soft-monomer Tg range. Claims 9 and 12 identify specific monomers.

Soft acrylic monomers

Claim 9 lists:

2-ethylhexyl acrylate
Isobutyl acrylate
Ethyl acrylate
Butyl acrylate
Dodecyl methacrylate
2-ethylhexyl methacrylate
2-ethoxyethyl acrylate
Isopropyl acrylate
2-methoxyethyl acrylate

Claims 7 and 8 narrow the soft-monomer Tg range to approximately -60°C to -20°C and -60°C to -24°C, respectively.

Hard acrylic monomers

Claim 12 lists:

Methacrylate
N-butyl acrylate
Acrylic acid
Butyl methacrylate
Ethyl methacrylate
Methyl methacrylate
Hexyl methacrylate
Methyl acrylate

The word "methacrylate" in claim 12 is potentially broader than a single named monomer. It does not automatically mean methacrylic acid. The express exclusion in claim 1 distinguishes methacrylic acid from methacrylate esters.

N-butyl acrylate appears in the hard-monomer list in claim 12 even though it is also commonly associated with soft, low-Tg acrylic behavior. That apparent technical tension does not eliminate the limitation. Claim construction would likely focus on the claim language, the patent specification, technical definitions, and the composition in the accused product. The official issued patent and prosecution history should control over any transcription error or informal monomer classification. (U.S. Patent No. 8,632,802.)

Does the patent cover blends with rubber or silicone adhesives?

Yes. Claim 13 permits the polymer composition to include a rubber-based or silicone-based polymer in addition to the acrylic-based polymer.

Claim 15 identifies possible rubber or silicone materials, including:

Natural or synthetic polyisoprene
Polybutylene
Polyisobutylene
Styrene-based polymers
Styrene block copolymers
Butadiene-based polymers
Styrene/butadiene polymers
Styrene-isoprene-styrene block copolymers
Hydrocarbon polymers
Halogen-containing polymers
Polysiloxanes

Claim 16 specifically covers polyisobutylene. Claim 17 covers polysiloxane polymers.

Claim 14 provides broad composition ranges:

Acrylic-based polymer: 2%-95% by weight of the transdermal system.
Rubber-based or silicone-based polymer: 4%-97% by weight.

Because the claim also requires drug loading and may involve backing or other patch components, these percentage ranges should be assessed against the complete composition and the patent's definitions of "transdermal drug delivery system" and "polymer composition."

What does claim 20 add to the patent scope?

Claim 20 is an independent composition claim with a different architecture. It requires:

A soft acrylic monomer selected from a specified list.
A hard acrylic monomer selected from a specified list.
Soft monomer at approximately 20%-70% by weight of the acrylic polymer.
Hard monomer at approximately 30%-80% by weight of the acrylic polymer.
Drug loading of 0.1%-50% by weight of the system.
No acrylic-based polymer polymerized with methacrylic acid.

The supplied text contains apparent transcription errors stating "620%" and "680%." Those values are technically implausible in context and appear to correspond to "20%" and "80%." The official issued patent must be used for litigation, freedom-to-operate, or prosecution analysis.

Claim 20 is important because its 20%-70% and 30%-80% ranges are broader than claim 1's 50%-70% and 30%-50% ranges. Its protection, however, depends on the specified monomer lists. A formulation outside those lists may avoid claim 20 while still implicating claim 1 if the Tg and ratio requirements are met.

What formulations are protected by U.S. Patent 8,632,802?

The patent's formulation coverage can be summarized as follows:

Formulation element	Claim coverage
Acrylic drug-in-adhesive system	Claims 1 and 20
Crystalline drug	Claim 2
Estradiol, norethindrone acetate, testosterone, scopolamine	Claim 3
Drug concentration of 0.3%-30%	Claim 4
Drug concentration of 0.5%-15%	Claim 5
Drug concentration of 1%-10%	Claim 6
Narrow soft-monomer Tg ranges	Claims 7-8
Named soft monomers	Claim 9
Narrow hard-monomer Tg ranges	Claims 10-11
Named hard monomers	Claim 12
Acrylic plus rubber or silicone polymer	Claims 13-17
Polyisobutylene blend	Claim 16
Polysiloxane blend	Claim 17
Backing layer	Claim 18
Transdermal administration	Claim 19

The claims do not expressly require a specific reservoir, membrane, release liner, permeation enhancer, crystallization inhibitor, patch size, dosing interval, or release profile. Those omissions broaden potential coverage but may limit the patent's ability to distinguish competing transdermal technologies based on performance characteristics alone.

When does U.S. Patent 8,632,802 lose exclusivity?

A U.S. utility patent generally expires 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments. The grant date, January 21, 2014, does not establish the expiration date. (35 U.S.C. §§ 154, 156.)

For this patent, the operative expiration date must be taken from the USPTO Patent Center record and the face of the issued patent. A patent-term adjustment could move the date later, while a terminal disclaimer could limit it to the expiration of another patent.

The patent can also lose practical exclusivity before expiration if:

The claims are invalidated.
The patent is held unenforceable.
A product design avoids every limitation of the asserted claim.
The patent is not listed for the relevant drug product and cannot support a listed-patent Paragraph IV challenge.
The patent expires but regulatory exclusivity or other patent rights remain separately relevant.

What is the Orange Book status of U.S. Patent 8,632,802?

A transdermal adhesive patent is not automatically an Orange Book-listed patent. FDA listing generally concerns patents that claim the approved drug substance, drug product, or an approved method of use and that are submitted by the NDA holder in accordance with FDA requirements. (FDA, 2024.)

A patent directed primarily to acrylic polymer composition may be difficult to list unless the claims are properly tied to the approved drug product or its approved use. Listing status must be checked separately for each NDA and drug product. Absence from the Orange Book does not necessarily eliminate infringement risk, but it can change the timing and mechanics of a generic challenge under the Hatch-Waxman framework.

What Paragraph IV challenges could target this patent?

A generic applicant could challenge the patent through an abbreviated new drug application if the patent is listed for the reference product. Potential grounds include:

Noninfringement based on a different acrylic monomer ratio.
Use of an acrylic polymer containing methacrylic acid.
Use of a nonacrylic adhesive.
Drug loading outside the claimed range.
Absence of the required soft or hard monomer.
Failure to satisfy the specified Tg range.
Lack of incorporation of the drug into the claimed polymer composition.
Invalidity for anticipation or obviousness.
Indefiniteness relating to "about," Tg values, or polymer-composition boundaries.
Written-description or enablement challenges to the full scope of the monomer and Tg ranges.

A Paragraph IV notice would not itself establish invalidity or noninfringement. The NDA holder could sue within the statutory period, potentially triggering a 30-month stay under the Hatch-Waxman framework. (21 U.S.C. § 355; 35 U.S.C. § 271(e)(2).)

What generic launch risks exist?

The highest generic entry risk exists for products that use:

A drug-in-acrylic adhesive format.
A 50:50 to 70:30 soft/hard acrylic balance.
The named monomers in claims 9 and 12.
No methacrylic acid in any acrylic polymer.
Estradiol, norethindrone acetate, testosterone, or scopolamine.
Drug loading within 0.5%-15%.
A polyisobutylene or silicone blend with the acrylic adhesive.

Risk is lower where the proposed generic uses:

A silicone-only or rubber-only adhesive.
A reservoir or matrix system without the claimed acrylic composition.
Methacrylic acid-containing acrylic polymers.
Monomer ratios outside both independent claims.
A different soft or hard monomer outside the claim 20 lists.
A drug concentration below 0.1% or above 50%, subject to product-performance constraints.

The most effective design-around strategy is likely a deliberately documented polymer formulation that uses methacrylic acid or a nonacrylic pressure-sensitive adhesive. That strategy may create separate regulatory, adhesion, irritation, crystallization, or performance issues.

How strong is the patent estate?

The patent has moderate formulation strength and narrower product-specific strength.

Strengths

Claim 1 combines chemical identity, Tg, composition percentages, drug loading, and a global methacrylic-acid exclusion.
Claims 2-18 provide multiple fallback positions.
Claim 20 supplies a second independent composition claim with broader percentage ranges.
The claims cover blends with polyisobutylene and polysiloxanes.
The claims are not limited to one therapeutic agent.

Weaknesses

Many limitations depend on technical measurements and approximate terms.
Tg values can vary with testing method, polymer architecture, molecular weight, and comonomer content.
"About" creates potential boundary disputes.
The exclusion of methacrylic acid offers a clear design-around.
The claims may face prior-art pressure because acrylic pressure-sensitive adhesives and drug-in-adhesive patches were established technologies before the patent's filing.
Claim 19 may provide limited incremental value because it depends on use of the device of claim 1 rather than adding a detailed administration regimen.

The patent is strongest against products that closely replicate the claimed polymer formulation and weakest against products using a different adhesive platform.

What patent litigation and settlement issues affect the patent?

A complete litigation assessment requires the USPTO Patent Center file, PACER records, district-court dockets, Federal Circuit decisions, and any ANDA litigation records tied to products covered by the patent. The claims alone do not establish whether U.S. Patent 8,632,802 has been asserted, invalidated, disclaimed, licensed, or included in a settlement.

For commercial diligence, the relevant checks are:

Issue	Why it matters
District-court litigation	Determines claim construction, validity rulings, and injunction exposure
ANDA Paragraph IV notices	Indicates imminent generic competition
Consent judgments	May restrict launch timing without a full merits decision
License agreements	Can create authorized generic or field-of-use rights
Terminal disclaimers	May shorten the effective patent term
Patent-term adjustment	May extend the nominal expiration date
Continuations and divisionals	May preserve related claims after the parent expires
Orange Book listing	Determines Hatch-Waxman notice and stay consequences

How does this patent compare with competing transdermal patent estates?

U.S. Patent 8,632,802 is a formulation and adhesive-composition patent. It differs from other transdermal patent categories:

Patent category	Typical protected subject matter	Relationship to 8,632,802
Drug-substance patent	Active pharmaceutical ingredient	Usually separate and earlier-expiring
Salt, polymorph, or crystal patent	Solid-state form of drug	May overlap with claim 2's crystalline-drug concept but is legally distinct
Adhesive patent	Polymer, tackifier, enhancer, or crosslinker	Closest competitive category
Device patent	Patch structure, backing, membrane, or reservoir	Potentially complementary
Method-of-use patent	Indication, dosing, or patient population	Claim 19 is broader but less clinically specific
Manufacturing patent	Polymerization, coating, drying, or lamination	Can create manufacturing barriers independent of product claims
Regulatory exclusivity	FDA exclusivity period	Separate from patent enforceability

The patent does not prevent all transdermal delivery. It targets a specific acrylic polymer formulation architecture.

Key Takeaways

Claims 1 and 20 are the principal composition claims.
The required soft/hard acrylic monomer balance is central to infringement.
The all-acrylic-polymers limitation excludes acrylic polymers polymerized with methacrylic acid.
Estradiol, norethindrone acetate, testosterone, and scopolamine receive narrower dependent-claim coverage.
Polyisobutylene and polysiloxane blends are expressly covered.
Claim 20 appears to contain transcription errors in the supplied text, particularly "620%" and "680%."
The patent is not automatically Orange Book listed because it primarily concerns adhesive formulation.
A Paragraph IV strategy could rely on noninfringement, invalidity, or both.
The clearest design-arounds are methacrylic-acid-containing acrylic polymers, nonacrylic adhesives, and monomer ratios outside both independent claims.
Exact expiration, terminal-disclaimer, continuation, litigation, licensing, and Orange Book conclusions require the official patent and regulatory records.

FAQs

Does U.S. Patent 8,632,802 cover all estradiol patches?

No. It covers estradiol patches only when the product also satisfies the claimed acrylic polymer, monomer, ratio, drug-loading, and methacrylic-acid exclusion limitations.

Can a patch avoid the patent by using a silicone adhesive?

Possibly. A silicone-containing product can still fall within claims 13-17 if it also contains the required acrylic polymer. A silicone-only system would generally avoid the acrylic-polymer limitations.

Does claim 2 require the drug to remain crystalline in the commercial patch?

Claim 2 expressly requires a crystalline drug. The relevant analysis would consider the claim construction and the physical state of the drug in the claimed transdermal system, including whether crystallinity is present as supplied or during use.

Can a formulation with acrylic acid avoid the patent?

Not automatically. Claim 12 lists acrylic acid as a hard acrylic monomer, while claim 1 excludes methacrylic acid monomers. Acrylic acid and methacrylic acid are different monomers. A formulation using acrylic acid must still satisfy the remaining limitations.

Is a patent expiration date the same as the date generic competition begins?

No. Generic entry can occur after patent expiration, through a license or settlement, after a successful Paragraph IV challenge, or under other authorized launch arrangements. FDA exclusivity and patent rights can also have different end dates.

References

U.S. Patent No. 8,632,802. (2014). Transdermal drug delivery system. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
United States Code. (2024). 21 U.S.C. § 355, New drugs.
United States Code. (2024). 35 U.S.C. § 154, Contents and term of patents; provisional rights.
United States Code. (2024). 35 U.S.C. § 156, Extension of patent term.
United States Code. (2024). 35 U.S.C. § 271(e)(2), Infringement of patents in regulated drug submissions.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2006041911	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,632,802

Summary for Patent: 8,632,802